Fifth Annual

COA-CCT Workshop

FDA U.S. FOOD & DRUG ADMINISTRATION
ONCOLOGY CENTER OF EXCELLENCE

ASCO®

SESSION 5 Project Patient Voice – Patient & Health Care Provider Perspectives

MODERATOR
Bellinda King-Kallimanis, PhD

Christine Hodgdon, MS

Lee Jones, MBA

Ashley J. Housten, OTD, MSCI

Karen L. Smith, MD, MPH

Adedayo A. Onitilo, MD, PhD, MSCR, FACP

#OCEOutcomes20

Ensuring PPV is User Friendly: Examples

Table 1. Summary of Symptom Frequency

Column A	Column B		Column C		Column D		Column E	
Symptom (Attribute)	No. of Patients[1]		Any symptom before treatment (%)[2]		Any Worsening on treatment (%)[3]		Worsening to Score 3 or 4 (%)[4]	
	Tagrisso	Chemo	Tagrisso	Chemo	Tagrisso	Chemo	Tagrisso	Chemo
Nausea (F)	80	44	25%	32%	41%	77%	6%	39%

The following is an example of how to interpret data for Nausea frequency in **Table 1:**

- **Column C:** Before starting treatment, 25% of patients who received Tagrisso reported having nausea (ranging from rarely to almost constantly).
- **Column D:** After starting treatment, 41% of patients who received Tagrisso reported their nausea had worsened (increased by at least 1 point on a 0 – 4 scale) at any time while on treatment.
- **Column E:** After starting treatment, 6% of patients who received Tagrisso reported their nausea had worsened to either occurring frequently or almost constantly at any time while on treatment.

https://www.fda.gov/about-fda/project-patient-voice/aura3

PPV User Guide

Figure 1. Patient-Reported Diarrhea During the First 24 Weeks on Treatment



Aim: To orient users on the elements of each chart

Figure 2. Worst Patient-Reported Nausea During the First 24 Weeks on Treatment



https://www.fda.gov/about-fda/project-patient-voice/interpretation-guide

Data Availability

For each stacked bar chart there is downloadable excel spreadsheet with the percent per response option by treatment arm

AURA3: Nausea

Share | Tweet | Linkedin | Email | Print

Project Patient Voice is intended to be used with a healthcare professional when discussing the potential symptoms related to a cancer and cancer treatment. Do not rely on Project Patient Voice alone to make decisions about medical care. Do not use Project Patient Voice to substitute for advice from your health care professional. Conclusions about patient experiences with symptoms may be limited because not all symptoms may have been captured by the patient-reported questionnaire.

← Back to summary table

Download symptom data (XLSX, 24KB)

	A	B	C	D	E	F	G	H	I	J	K	L	M
1	**Symptom**	**Nausea**											
2	**Figure 1: Patient-Reported Nausea During the first 24 Weeks on Treatment**												
3		**Tagrisso**						**Chemotherapy**					
4	**Time**	**N**	**Never (%)**	**Rarely (%)**	**Occasionally (%)**	**Frequently (%)**	**Almost Constantly (%)**	**N**	**Never (%)**	**Rarely (%)**	**Occasionally (%)**	**Frequently (%)**	**Almost Constantly (%)**
5	Baseline	81	75	10	7	6	1	47	66	26	0	6	2
6	Week 1	86	78	8	9	2	2	37	41	24	11	16	8
7	Week 2	89	80	13	6	1	0	48	40	25	17	15	4
8	Week 3	92	83	11	7	0	0	49	53	29	12	2	4
9	Week 4	88	85	8	7	0	0	45	40	29	20	11	0
10	Week 5	81	88	9	2	1	0	41	49	22	15	10	5
11	Week 6	91	81	13	4	0	1	40	45	30	20	5	0
12	Week 7	84	83	13	2	1	0	43	51	30	9	9	0

All patients | No symptom at baseline patients

Patients Who Are Like Me

- Subgroups can be small, therefore generalizations are difficult

- One subgroup included on PPV:
  - Patients with no symptoms at baseline

Figure 3. Patient-Reported Nausea During the First 24 Weeks on Treatment: Patients Without Nausea Before Treatment



Have a Question?

Type your question in the Q&A box and we will answer as many questions as we can

Questions we can’t get to and other feedback will noted and reviewed as part of our review process for Project Patient Voice

SESSION 5 Project Patient Voice – Patient & Health Care Provider Perspectives

The Patient Perspective

Christine Hodgdon, MS

- **How do you see yourself using this website?**
- **From your perspective, how much detail do patients need versus balancing this with simplicity?**
- **What additional information might help orient users in reading the charts?**

Lee Jones, MBA

SESSION 5 Project Patient Voice – Patient & Health Care Provider Perspectives

The Clinician Perspective

Karen L. Smith, MD, MPH

- **How do you see yourself using this resource in your clinic workflow?**
- **Which elements of the website do you see yourself utilizing most?**
- **Where is there room for improvement?**

Adedayo A. Onitilo, MD, PhD, MSCR, FACP

SESSION 5 Project Patient Voice – Patient & Health Care Provider Perspectives

Ashley J. Housten, OTD, MSCI

- **Given your experience with developing shared decision making tools, how could we make this website more user friendly?**

Project Patient Voice

Project Patient Voice is an online platform for patients and caregivers along with their healthcare providers to look at patient-reported symptom data collected from cancer clinical trials.

What is the purpose of Project Patient Voice?

Why is this needed?

What is the source of this patient-reported symptom information?

What is the difference between patient-reported symptom information and the safety information in the drug label?

What is the Pilot Phase of Project Patient Voice?

How to use Project Patient Voice

Limitations of Project Patient Voice

Can my experience with symptoms be added to this information?

Where can I send comments or questions about Project Patient Voice?

Trial Name	Disease Type	Drug	Study Design	Blinding Status	Comparator Arm	Patient Questionnaire Used to Collect Symptom Data	FDA Label
AURA3	Advanced non-small cell lung cancer with EGFR mutation	TAGRISSO	Randomized	Open label	Platinum-based doublet chemotherapy	PRO-CTCAE	Here

AURA3

Project Patient Voice is intended to be used with a healthcare professional when discussing the potential symptoms related to a cancer and cancer treatment. Do not rely on Project Patient Voice alone to make decisions about medical care. Do not use Project Patient Voice to substitute for advice from your health care professional. Conclusions about patient experiences with symptoms may be limited because not all symptoms may have been captured by the patient-reported questionnaire.

How Was the AURA3 Study Conducted?

AURA3 is a Phase III, open label, randomized study comparing TAGRISSO™ with platinum-based doublet chemotherapy. To be included in AURA3, patients had an abnormal epidermal growth factor receptor (EGFRm+/T790M+) lung cancer that had spread to other parts of the lungs or body (locally advanced or metastatic non-small cell lung cancer - NSCLC) and had previously been treated with an approved EGFR-TKI medicine that had stopped working or did not work. Patients were allocated by a ratio of 2:1 Tagrisso: chemotherapy. For more information on how this study was conducted, refer to the product label.

Which Questionnaire Was Used to Collect Patient-Reported Symptoms?

Patients reported their symptom experiences via the Patient Reported Outcomes – Common Terminology Criteria for Adverse Events (PRO-CTCAE) questionnaire. PRO-CTCAE was developed by the National Cancer Institute (NCI) to evaluate symptomatic toxicity in patients in oncology clinical trials. The PRO-CTCAE questionnaire was designed to provide additional information that is complementary to existing safety and tolerability assessments reported by clinicians.

How Were Patient-Reported Symptoms in the AURA3 Study Collected?

Patients reported their symptom experiences just before treatment and each week during treatment, using the PRO-CTCAE questionnaire. PRO-CTCAE data was collected from 102 patients randomized to Tagrisso and 59 patients randomized to chemotherapy for whom PRO-CTCAE was available in their language (English, Spanish, Japanese, and German). Twenty-eight symptoms were selected based on their relevance to known side-effects of treatment with Tagrisso, similar EGFR-TKI agents or chemotherapy. Each symptom is asked as either a frequency, severity, occurrence, or amount question. At each assessment week over the first 24 weeks (approximately 6 months) of treatment, between 71.4% to 89.8% of patients provided data. Three patients did not provide any data at any of these weeks, and for that reason are not included in the analysis.

Which Symptoms Were Reported by Patients While on Treatment?

Table 1 presents the PRO-CTCAE questionnaire results from the AURA3 study. The columns summarize the proportion (percentage) of patients who:

- **Column C:** had any symptom before starting treatment, by treatment arm
- **Column D:** reported any worsening of their symptoms compared to before treatment, by treatment arm
- **Column E:** reported worsening to a score 3 or 4 (on a 0 – 4 scale) compared to before treatment, by treatment arm

Table 1 Key

Symptom Attribute Scoring				
Score	**Amount (A)**	**Frequency (F)**	**Severity/Intensity (S)**	**Occurrence (O)**
0	Not at all	Never	None	No
1	A Little Bit	Rarely	Mild	Yes
2	Somewhat	Occassionally	Moderate	N/A
3	Quite a Bit	Frequently	Severe	N/A
4	Very Much	Almost Constantly	Very Severe	N/A

Table 1. Summary of Symptom Frequency

Column A	Column B		Column C		Column D		Column E	
Symptom (Attribute)	**No. of Patients[1]**		**Any symptom before treatment (%)[2]**		**Any Worsening on treatment (%)[3]**		**Worsening to Score 3 or 4 (%)[4]**	
	Tagrisso	**Chemo**	**Tagrisso**	**Chemo**	**Tagrisso**	**Chemo**	**Tagrisso**	**Chemo**
Loose or Watery Stools (F)	80	44	31%	39%	70%	61%	19%	16%
Numbness or Tingling in Hands or Feet (S)	80	44	24%	30%	59%	50%	3%	7%
Pain in the Abdomen (F)	80	44	19%	43%	59%	61%	9%	14%
Fatigue, Tiredness or Lack of Energy (S)	80	44	64%	70%	58%	73%	24%	45%
Hand-Foot Syndrome (S)	80	44	31%	30%	54%	43%	5%	5%
Acne or Pimples on the Face or Chest (S)	80	44	36%	30%	53%	32%	0%	0%
Dry Mouth (S)	80	44	43%	43%	50%	68%	11%	20%
Mouth and Throat Sores (S)	80	44	21%	18%	48%	66%	9%	11%
Arm or Leg Swelling (F)	80	44	15%	20%	46%	45%	10%	16%
Itchy Skin (S)	80	44	48%	55%	46%	39%	5%	2%
Rash (O)	80	44	35%	20%	46%	34%	N/A	N/A
Dry Skin (S)	80	44	73%	77%	44%	34%	6%	2%
Nausea (F)	80	44	25%	32%	41%	77%	6%	39%
Blurry Vision (S)	80	44	29%	32%	39%	52%	3%	9%

Nausea (F)	80	44	25%	32%	41%	77%	6%	39%
Blurry Vision (S)	80	44	29%	32%	39%	52%	3%	9%
Decreased Appetite (S)	80	44	54%	52%	39%	68%	10%	30%
Constipation (S)	80	44	43%	45%	38%	64%	10%	32%
Ridges or Bumps on your Fingernails or Toenails (O)	80	44	30%	34%	38%	30%	N/A	N/A
Problems Tasting Food or Drink (S)	80	44	24%	30%	36%	73%	6%	27%
Change in Color of your Fingernails or Toenails (O)	80	44	6%	7%	36%	32%	N/A	N/A
Skin Cracking at Corners of your Mouth (S)	80	44	14%	2%	34%	48%	5%	5%
Bruise Easily (O)	80	44	6%	23%	33%	32%	N/A	N/A
Nosebleeds (F)	80	44	11%	18%	31%	36%	4%	2%
Shivering or Shaking Chills (F)	80	44	26%	25%	29%	50%	6%	7%
Lose Control of Bowel Movements (F)	80	44	6%	14%	28%	36%	8%	2%
Increased Skin Sensitivity to Sunlight (O)	80	44	16%	9%	28%	30%	N/A	N/A
Vomiting (F)	80	44	13%	20%	25%	59%	4%	16%
Lose any Fingernails or Toenails (O)	80	44	14%	14%	23%	20%	N/A	N/A
Hair Loss (A)	80	44	20%	20%	20%	30%	1%	2%

Attributes: A = Amount; F = Frequency; O = Occurrence; S = Severity/Intensity
Chemo = Chemotherapy; N/A = Not Applicable (For symptoms with Occurrence attribute, worsening to score 3 or 4 is not applicable, as responses are either Yes or No)

[1] No. of Patients: The number of patients who provided a score before treatment and at least one on-treatment score (between weeks 1-24).
[2] Any Symptom Before Treatment (%): The percentage of patients whose symptom score before treatment was 1-4.
[3] Any Worsening (%): The percentage of patients whose symptom score increased during treatment, with respect to their score before treatment.
[4] Worsening to Score 3 or 4 (%): The percentage of patients whose symptom score increased to 3 or 4 during treatment, with respect to their score before treatment.

The following is an example of how to interpret data for Nausea frequency in **Table 1:**

- **Column C:** Before starting treatment, 25% of patients who received Tagrisso reported having nausea (ranging from rarely to almost constantly).
- **Column D:** After starting treatment, 41% of patients who received Tagrisso reported their nausea had worsened (increased by at least 1 point on a 0 – 4 scale) at any time while on treatment.
- **Column E:** After starting treatment, 6% of patients who received Tagrisso reported their nausea had worsened to either occurring frequently or almost constantly at any time while on treatment.

AURA3: Nausea

Project Patient Voice is intended to be used with a healthcare professional when discussing the potential symptoms related to a cancer and cancer treatment. Do not rely on Project Patient Voice alone to make decisions about medical care. Do not use Project Patient Voice to substitute for advice from your health care professional. Conclusions about patient experiences with symptoms may be limited because not all symptoms may have been captured by the patient-reported questionnaire.

← Back to summary table

Download symptom data (XLSX, 24KB)

In AURA3 Study, Patients Were Asked: "In the last 7 days, how OFTEN did you have NAUSEA?"

Patients scored the frequency of their Nausea on a 5-point scale (Never, Rarely, Occasionally, Frequently, Almost Constantly)

Patient-Reported Nausea During the First 24 Weeks on Treatment for Patients Who Completed a Questionnaire:

Figure 1 shows the percentage of patients reporting how often they had Nausea at each time point. For example, at week 2, 20% of patients taking Tagrisso reported Nausea (ranging from Rarely to Frequently). The range of patients who had any Nausea during the first 24 weeks of treatment with Tagrisso was between 12% - 29%. Click here for more information on how to read the graphs below.

Figure 1. Patient-Reported Nausea During the First 24 Weeks on Treatment



All responses from patients' experiences just before and up to week 24 on-treatment were included in the analysis. Some patients did not report their symptoms every week, therefore the number of patients may vary between weeks. Furthermore, not all patients remained on the treatment for 24 weeks (e.g., some stop treatment for worsening disease) which is a reason for the change in the number of patients over the course of treatment.

Worst Response Option for Nausea That Patients Reported During the First 24 Weeks on Treatment

Figure 2. Worst Patient-Reported Nausea During the First 24 Weeks on Treatment



Patients with at least one on-treatment Nausea score were included in the analysis. Tagrisso (N=99), Chemotherapy (N=55).

Some Patients Did Not Report Nausea Before Treatment:

For patients that did not report Nausea before treatment, Figure 3 shows the percentage of patients reporting how often they had Nausea between weeks 1 and 24.

Figure 3. Patient-Reported Nausea During the First 24 Weeks on Treatment: Patients Without Nausea Before Treatment



All responses from patients who did not report Nausea before treatment were included in the analysis. Some patients did not report their symptoms every week, therefore the number of patients may vary between weeks. Furthermore, not all patients remained on the treatment for 24 weeks (e.g., some stop treatment for worsening disease) which is a reason for the change in the number of patients over the course of treatment.

Worst Response Option for Nausea That Patients Reported During the First 24 Weeks on Treatment, for Patients Who Did Not Have Nausea Before Treatment:

Figure 4. Worst Patient-Reported Nausea During the First 24 Weeks on Treatment: Patients Without Nausea Before Treatment



Patients who had no Nausea before treatment and at least one on-treatment Nausea score were included in the analysis. Tagrisso (N=60), Chemotherapy (N=30).